Transcription of MYCのタンパク発現量を基軸とした高悪性度B細胞 …
1 165 43 2 29 3 1) 2) B DLBCL 1) DLBCL Germinal center B-cell GCB Activated B-cell ABC 2 IHC 2, 3) MYC Burkitt DLBCL MYC 4) MYC BCL2 BCL6 double hit lymphoma/triple hit lymphoma DHL/THL 5) MYC cut off 3 3 -diaminobenzidine DAB IHC PID Phosphor Integrated Dot PID 10000 10 6) DAB IHC 1) MYC 2002 - 2015 R - CHOP DLBCL FFPE TMA TMA MYC clone Y69 Rabbit monoclonal Epitomics, Inc.
2 IHC MYC IHC - DAB 3 DAB MYC 40 % 40 % 40 DLBCL EZR 2) PID MYC MYC 5 Burkitt MYC Cell block MYC IHC DAB MYC - DAB PID MYC - PID DLBCL40 1) PID MYC Burkitt DAB IHC - DAB MYC MYC IHC - DAB 27 MYC B 1) 1) 2)166 B High grade B-cell lymphoma NOS 9) MYC DLBCL B MYC PID MYC DLBCL R - CHOP 40 PID MYC DAB PID MYC MYC MYC MYC MYC PID MYC MYC 1) WHO Classification of Tumours of Haematopietic and Lymphoid Tissues.
3 Lyon France: IARC; 2008: 233 - ) Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503 - ) Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004 103: 275 - Cai Q, Medeiros LJ, Xu X, Young KH. MYC - driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. Oncotarget 2015 Nov 17; 6(36): 38591 - ) Abramson JS. The Spectrum of Double Hit Lymphomas. Hematol Oncol Clin North Am. 2016 Dec; 30(6): 1239 - ) KONICA MINOLTA TECHNOLOGY REPORT, 2014(11): 68 ) Guti rrez - Garc a G, Cardesa - Salzmann T, Climent F, Gonz lez - Barca E, Mercadal S, Mate JL et al.
4 MYC - PID MYC - PID MYC - DAB MYC - PID MYC - PID MYC - DAB 1 MYC - PID 2) DLBCL MYC-PID MYC DLBCL MYC - DAB MYC - PID IHC MYC - DAB 40 % DLBCL40 DLBCL MYC - DAB PID MYC p< DAB IHC DLBCL 2000 GCB ABC IHC CD10 BCL6 MUM1 3 GCB non - GCB GCB non - GCB 7) FISH DLBCL MYC 8) WHO MYC BCL2 BCL6 High grade B - cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement MYC 1.
5 IHC - DABIHC - PID167 MYC B Gene - expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B -cell lymphoma treated with immunochemotherapy. Blood 2011; 117(18): 4836 - ) Copie - Bergman C, Cuilli re - Dartigues P, Baia M, Briere J, Delarue R, Canioni D, Salles G, Parrens M, et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood 2015 Nov 26; 126(22): 2466 - ) Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid 2016 May 19; 127(20): 2375 - 90. 1) MYC 105 28 5 2017 The Medical Society of Saitama Medical
